6 Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

7 Vedolizumab as induction and maintenance therapy for ulcerative colitis

8 Specific detection of bifidobacterium strains in a pharmaceutical probiotic product and in human feces by polymerase chain reaction

9 Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

10 Deep remission in inflammatory bowel disease: looking beyond symptoms

11 Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab

12 Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease

13 Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

14 Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease

15 Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications

16 Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea

17 Treatment Targets in Inflammatory Bowel Disease: Current Status in Daily Practice

18 Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis

19 Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC

20 Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

21 Mucosa-associated bacterial flora of the human colon

22 Antibacterial antibodies in rectal and colonic mucosa in ulcerative colitis

23 Associations of sense of coherence with psychological distress and quality of life in inflammatory bowel disease

24 Pouchitis: result of microbial imbalance?

25 Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response

26 Inflammatory bowel disease

27 Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

28 Effects of Jianpi Qingchang decoction on the quality of life of patients with ulcerative colitis: A randomized controlled trial

29 Adhesive and hydrophobic properties of Escherichia coli from the rectal mucosa of patients with ulcerative colitis

30 Potential molecular biomarkers used to predict the response to biological therapies in ulcerative colitis

31 Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease

32 Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial

33 Anti-Colitic Effects of Ethanol Extract of Mill. through Suppression of Pro-Inflammatory Mediators via NF-κB/STAT3 Inactivation in Dextran Sulfate Sodium-Induced Colitis Mice.

34 Effect of Shogaol on the Expression of Intestinal Stem Cell Markers in Experimentally Induced Colitis in BALB/c Mice

35 The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis

36 The Clinical and Steroid-Free Remission of Fecal Microbiota Transplantation to Patients with Ulcerative Colitis: A Meta-Analysis

37 Therapeutic effect of gold nanoparticles on DSS-induced ulcerative colitis in mice with reference to interleukin-17 expression

38 Differential Intestinal Mucosa Transcriptomic Biomarkers for Crohn’s Disease and Ulcerative Colitis

39 Distinct patterns of naive, activated and memory T and B cells in blood of patients with ulcerative colitis or Crohn's disease.

40 Consenso mexicano para el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática

41 Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition.

42 The combination of indirubin and isatin attenuates dextran sodium sulfate induced ulcerative colitis in mice.

43 Protective effect of Lactobacillus fermentum CQPC04 on dextran sulfate sodium-induced colitis in mice is associated with modulation of the nuclear factor-κB signaling pathway.

44 Endoscopy in Postoperative Patients with Crohn's Disease or Ulcerative Colitis. Does It Translate to Better Outcomes?

45 [Method of diagnosis of the severity of the disease attack in patients with ulcerative colitis.]

46 Costus root granules improve ulcerative colitis through regulation of TGF-β mediation of the PI3K/AKT signaling pathway.

47 Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis

48 Appropriate Timing of Discontinuation of Tacrolimus Therapy for Refractory Ulcerative Colitis

49 Ambient air quality as risk factor for microscopic colitis - A geographic information system (GIS) study.

50 Application of a DSS colitis model in toxicologically assessing norisoboldine.

51 Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam.

52 Analgesic effect of resveratrol on colitis-induced visceral pain via inhibition of TRAF6/NF-κB signaling pathway in the spinal cord.

53 Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial.

54 Cyanidin-3--Glucoside and Cyanidin Protect Against Intestinal Barrier Damage and 2,4,6-Trinitrobenzenesulfonic Acid-Induced Colitis.

55 Microscopic colitis: diagnosis and management.

56 Healing effects of Cornus mas L. in experimentally induced ulcerative colitis in rats: From ethnobotany to pharmacology.

57 Healing effects of Cornus mas L. in experimentally induced ulcerative colitis in rats: From ethnobotany to pharmacology

58 Modulation of gut microbiota by Ilex kudingcha improves dextran sulfate sodium-induced colitis.

59 Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis.

60 Decreasing Colectomy Rates in Ulcerative Colitis in the Past Decade: Improved Disease Control?

61 Saccharomyces cerevisiaeCNCMI-3856 prevents colitis induced by AIEC bacteria in the transgenic mouse model mimicking Crohn's disease

62 AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition

63 Tu2024 AIEC Instigates Chronic Colitis by Altering Microbiota Composition and Its Inherent Pro-Inflammatory Potential

64 Sa1753 Vertical Transmission of AIEC Pathobiont Increases Severity of DSS-Induced Colitis in Offspring

65 Characteristics and outcomes of acute colitis diagnosed on cross-sectional imaging presenting via the emergency department in an Irish academic medical centre.

66 Functional and quality of life outcomes after ileal pouch-anal anastomosis in short versus long ileal J-pouch configuration in ulcerative colitis patients: a cohort study.

67 Filtered Kombucha tea ameliorates the leaky gut syndrome in young and old mice model of colitis.

68 Therapeutic effect of adenosine on experimentally induced acute ulcerative colitis model in rats.

69 Tricellulin is regulated via interleukin-13-receptor α2, affects macromolecule uptake, and is decreased in ulcerative colitis

70 Orally administered gold nanoparticles protect against colitis by attenuating Toll-like receptor 4- and reactive oxygen/nitrogen species-mediated inflammatory responses but could induce gut dysbiosis in mice.

71 Maternal High Fat Diet Alters Gut Microbiota of Offspring and Exacerbates DSS-Induced Colitis in Adulthood

72 Ulcerative Colitis: A Critical Approach to the Global Research Output Employing Density-equalizing Mapping and Scientometric Methods.

73 Effects of Aqueous and Methanolic Extracts of Stem Bark of De Wild. (Apocynaceae) on Dextran Sodium Sulfate-Induced Ulcerative Colitis in Wistar Rats.

74 Rapid expansion of Treg cells protects from collateral colitis following a viral trigger

75 Risk factors for ulcerative colitis-associated colorectal cancer: A retrospective cohort study.

76 Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1

77 Chemotaxonomic Analysis of Bacterial Populations Colonizing the Rectal Mucosa in Patients with Ulcerative Colitis

78 Inflammatory colonic carcinogenesis: A review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis

79 Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

80 Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis

81 Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

82 Psychological status in Iranian patients with ulcerative colitis and its relation to disease activity and quality of life

83 Psychological status in Iranian patients with ulcerative colitis and its relation to disease activity and quality of life

84 Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients

85 nrf-2 expression in ulcerative colitis lesions and its correlation with antioxidant enzyme levels and tissue injury

86 reactive oxygen species deficiency due to ncf1-mutation leads to development of adenocarcinoma and metabolomic and lipidomic remodeling in a new mouse model of dextran sulfate sodium-induced colitis

87 pseudomembranous colitis: not always caused by clostridium difficile

88 the crohn’s and colitis foundation of canada: a time for reflection and strategic planning for the future

89 intestinal anti-inflammatory effects of outer membrane vesicles from escherichia coli nissle 1917 in dss-experimental colitis in mice

90 possibility of interstitial lung disease as a phlebosclerotic colitis manifestation

91 sucralose promotes colitis-associated colorectal cancer risk in a murine model along with changes in microbiota

92 boehmeria nivea attenuates the development of dextran sulfate sodium-induced experimental colitis

93 markers of hypoxia correlate with histologic and endoscopic severity of colitis in inflammatory bowel disease

94 paraoxonase and arylesterase activities, lipid profile, and oxidative damage in experimental ischemic colitis model

95 expressing the differences between crohn disease and ulcerative colitis.

96 adrenal-derived hormones differentially modulate intestinal immunity in experimental colitis

97 intestinal giardiasis disguised as ulcerative colitis

98 cause for controversy? infliximab in the treatment of ulcerative colitis: an update

99 decreased breg/th17 ratio improved the prognosis of patients with ulcerative colitis

100 cd47 is a negative regulator of intestinal epithelial cell self-renewal following dss-induced experimental colitis

101 topical treatment of ulcerative colitis using enemas containing 5-aminosalicylic acid and beclomethasone dipropionate

Keyword Connections

Journals

Research Groups

Bibliographies